
Scientists from the German Cancer Research Center (DKFZ) and the stem cell institute HI-STEM* in Heidelberg have succeeded for the first time in directly reprogramming human blood cells into a previously unknown type of neural stem cell.
These induced stem cells are similar to those that occur during the early embryonic development of the central nervous system. They can be modified and multiplied indefinitely in the culture dish and can represent an important basis for the development of regenerative therapies.
Stem cells are considered to be the all-rounders of our tissues: they can multiply indefinitely and then – if they are pluripotent embryonic stem cells – generate all conceivable cell types. In 2006, the Japanese scientist Shinya Yamanaka recognized that such cells could also be produced in the laboratory – from mature body cells. Four genetic factors alone are sufficient to reverse the course of development and produce so-called induced pluripotent stem cells (iPS) that have identical properties to embryonic stem cells. Yamanaka was awarded the Nobel Prize for Medicine in 2012 for this discovery.
“This was a major breakthrough for stem cell research,” said Andreas Trumpp, German Cancer Research Center (DKFZ) and Director of HI-STEM in Heidelberg. “This applies in particular to for research in Germany, where the generation of human embryonic stem cells is not permitted. Stem cells have enormous potential both for basic research and for the development of regenerative therapies that aim to restore diseased tissue in patients. However, reprogramming is also associated with problems: For example, pluripotent cells can form germ line tumors, so-called teratomas.
Another possibility is not to completely turn back the course of development. For the first time, Trumpp’s team has succeeded in reprogramming mature human cells in such a way that a defined type of induced neural stem cells is produced that can multiply almost indefinitely. “We used four genetic factors like Yamanaka, but different ones for our reprogramming,” explains Marc Christian Thier, first author of the study. “We assumed that our factors would allow reprogramming to an early stage of development of the nervous system.”
In the past, other research groups also reprogrammed connective tissue cells into mature nerve cells or neural precursor cells. However, these artificially produced nerve cells often could not be expanded and could therefore hardly be used for therapeutic purposes. “Often, it was a heterogeneous mixture of different cell types that might not exist in the body under physiological conditions,” said Andreas Trumpp explaining the problems.
Together with stem cell researcher Frank Edenhofer from the University of Innsbruck and neuroscientist Hannah Monyer from DKFZ and the Heidelberg University Hospital, Trumpp and his team have succeeded in reprogramming different human cells: connective tissue cells of the skin or pancreas as well as peripheral blood cells. “The origin of the cells had no influence on the properties of the stem cells,” said Thier. In particular, the possibility of extracting neural stem cells from the blood of patients without invasive intervention is a decisive advantage for future therapeutic approaches.
What is special about the reprogrammed cells of the Heidelberg researchers is that they are a homogeneous cell type that resembles a stage of neural stem cells that occurs during the embryonic development of the nervous system. “Corresponding cells exist in mice and probably also in humans during early embryonic brain development,” said Thier. “We have described here a new neural stem cell type in the mammalian embryo.
These so called “induced Neural Plate Border Stem Cells” (iNBSCs) have a broad development potential. The iNBSCs of the Heidelberg scientists are expandable and multipotent and can develop in two different directions. On the one hand, they can take the path of development to mature nerve cells and their supplier cells, the glial cells, i.e. become cells of the central nervous system. On the other hand, they can also develop into cells of the neural crest, from which different cell types emerge, for example peripheral sensitive nerve cells or cartilage and bones of the skull.
The iNBSCs thus form an ideal basis for generating a broad range of different cell types for an individual patient. “These cells have the same genetic material as the donor and are therefore presumably recognized as “self” by the immune system and are not rejected,” explains Thier.
The CRISPR/Cas9 gene scissors can be used to modify the iNBSC or repair genetic defects, as the scientists have shown in their experiments. “They are therefore of interesting both for basic research and the search for new active substances and for the development of regenerative therapies, for example in patients with diseases of the nervous system. However until we can use them in patients, a lot of research work will still be necessary,” emphasizes Trumpp.
Learn more:Â An important step for regenerative medicine: Human blood cells can be directly reprogrammed into neural stem cells
The Latest on: Regenerative medicine
[google_news title=”” keyword=”regenerative medicine” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]
via Google News
The Latest on: Regenerative medicine
- Orthocell ramps up global expansion of market-leading regenerative medicine productson July 23, 2024 at 9:35 pm
Orthocell (ASX:OCC) has ramped up efforts to tap into the lucrative global markets for its two key products – Striate+ for guided bone and tissue regeneration in dental implant procedures and Remplir ...
- SkinGenuity leads the way in Regenerative Aestheticson July 23, 2024 at 6:37 am
SkinGenuity, LLC CEO, Paul Guilbaud, MBA, joined Gayle Guyardo, the host of the global health and wellness show, Bloom, to share more about how they are leading the way in ...
- AffyImmune Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for AIC100 in Recurrent Anaplastic Thyroid Canceron July 23, 2024 at 5:00 am
AffyImmune Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for AIC100 in Recurrent Anaplastic Thyroid Cancer ...
- BioRestorative Therapies’ Chief Scientist Named New Section Editor of the Prestigious Journal of Translational Medicineon July 23, 2024 at 12:10 am
New journal section will focus on emerging and translation work in the field of regenerative medicine - MELVILLE, N.Y., July 23, 2024 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc.
- UK Regenerative Therapy Specialist Discusses New Treatments In Debut Bookon July 22, 2024 at 12:22 pm
Regeneration Man creator Professor Paul Lee, PhD, MSc, MBBch, MRCS, MFSEM (UK), explains the roles physics, chemistry, biology, and time play ...
- Regenera Activa, DMark Beauty revolutionize hair care with regenerative medicineon July 21, 2024 at 10:01 am
GONE are the problems of hair loss and thinning with the new regenerative solution, crafted and distributed by Regenera Activa and DMark Beauty Corp. The new Rigenera technology utilizes the ...
- Regenerative Medicine Market Is Expected to Expand, with a CAGR of 18.5% From 2023 to 2033 | FMIon July 19, 2024 at 6:31 am
Regenerative Medicine MarketThe field of Regenerative Medicine Market, offering the potential to heal and repair damaged tissues and organs, is experiencing remarkable growth. According to a new ...
- Lynch Regenerative Medicine Completes Series A Financingon July 17, 2024 at 3:36 pm
Lynch Regenerative Medicine, LLC (LRM) has completed its Series A financing to develop and commercialize innovative skin rejuvenation and regeneration solutions based on the only tissue growth factor ...
- Could Regenerative Medicine Be An Innovative Approach In The Treatment Of Non-Obstructive Azoospermia?on July 16, 2024 at 4:47 am
According to a doctor, non-obstructive azoospermia affects about 10-15 per cent of infertile men. Unlike obstructive azoospermia where there are blockages, NOA results from 'intrinsic testicular ...
- The Local Doctor is in for Everyday Solutions: Regenerative Medicineon July 13, 2024 at 12:47 pm
The Local Doctor is in for everyday solutions! Dr. Ira Zunin was back in the studio for Good Morning Hawaii to discuss Regenerative Medicine.
via Bing News